Hindson Benjamin J.'s Form 4 filing
10x Genomics, Inc. (TXG) · filed Nov 23, 2022
- Accession no.
- 0001567619-22-020870
- Filed
- Nov 23, 2022
- Trade date
- Nov 22, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $80.4K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hindson Benjamin J.CIK 0001786391 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 22, 2022 | Class A Common Stock | SSaleDisposed | −359 | $34.07 | −$12,231.13 | 219,715 | Direct | |
| Nov 22, 2022 | Class A Common Stock | SSaleDisposed | −915 | $34.07 | −$31,174.05 | 218,800 | Direct | |
| Nov 22, 2022 | Class A Common Stock | SSaleDisposed | −1,087 | $34.07 | −$37,034.09 | 217,713 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
President and Chief Scientific Officer